her2-Amplification – Medical News Asia

HER2 Unraveled—The Vital Distinction Between Overexpression and Gene Amplification in Cancer

11 December 2025/in HER2, HER2 Explorer 2nd Homepage/by Reema Subramanian

Human epidermal growth factor receptor 2 (HER2) is a crucial biomarker in contemporary cancer management. Alterations in the HER2 protein or in the protein-coding gene, erythroblastic leukemia viral oncogene homolog 2 (ERBB2; hereafter referred to as HER2 in line with common practice), have significant clinical implications. Overexpression of the HER2 protein, gene amplification or activating mutations can overactivate or enhance downstream HER2 signaling pathways. Increased HER2 signaling drives key processes in tumorigenesis, including cellular transformation, survival, proliferation, and invasion.

Navigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker Assessment

31 July 2025/in HER2 Explorer, Breast Cancer 2nd Homepage/by Stijn van den Borne, MSc

Due to the availability of human epidermal growth factor receptor 2 (HER2)-directed therapies, testing for HER2 alterations, including overexpression, gene amplification or mutations is recommended in treatment guidelines for various tumor types, including breast cancer, gastric cancer, biliary tract cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.1-10

HER2 as a biomarker in cancers

16 July 2024/in HER2 Explorer 2nd Homepage/by Jessica LAU

Human epidermal growth factor receptor-2 (HER2) is a member of the erythroblastic oncogene B (ERBB) family of transmembrane tyrosine kinase receptors that also includes epidermal growth factor receptor (EGFR, also known as HER1), and human epidermal growth factor receptors -3 and -4 (HER3, HER4).1,2 Despite being a receptor, HER2 has no known ligand, but its conformation is similar to the ligand-activated form of other ERBB family members, favoring heterodimerization with them.1,3

Tag Archive for: her2-Amplification